Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy Batchelor

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of Neuro-Oncology|July 20, 2002
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitisKurt A Jaeckle, Tracy Batchelor, Steven J O'Day, et al.
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.
Journal of Neuro-Oncology|August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Ocular Immunology and Inflammation|May 19, 2021
Consensus Recommendations for the Diagnosis of Vitreoretinal LymphomaDenise Carbonell, Sarakshi Mahajan, Soon-Phaik Chee, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Nature|October 18, 2023
Clinical trial links oncolytic immunoactivation to survival in glioblastomaAlexander L Ling, Isaac H Solomon, Ana Montalvo Landivar, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of Neuro-Oncology|July 20, 2002
An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitisKurt A Jaeckle, Tracy Batchelor, Steven J O'Day, et al.
Cancer|September 11, 2014
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphomaYi-Bin Chen, Tracy Batchelor, Shuli Li, et al.
Journal of Neuro-Oncology|August 29, 2019
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201Andrew S Chi, Rohinton S Tarapore, Matthew D Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Ocular Immunology and Inflammation|May 19, 2021
Consensus Recommendations for the Diagnosis of Vitreoretinal LymphomaDenise Carbonell, Sarakshi Mahajan, Soon-Phaik Chee, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Nature|October 18, 2023
Clinical trial links oncolytic immunoactivation to survival in glioblastomaAlexander L Ling, Isaac H Solomon, Ana Montalvo Landivar, et al.
Pageof 6